Experimental Dual-Target CAR T-Cell therapy shows promise for Tough-to-Treat lymphoma
NCT ID NCT05149391
First seen Feb 01, 2026 · Last updated Apr 29, 2026 · Updated 11 times
Summary
This early-phase study tested a new type of immunotherapy called C-CAR039 in 3 adults with relapsed or refractory B-cell non-Hodgkin's lymphoma. The therapy uses a patient's own immune cells, modified to attack two cancer targets (CD19 and CD20) at once. The main goal was to check safety and side effects, while also measuring how long the cells last in the body. Because lifelong monitoring or additional treatment may still be needed, this approach is considered disease control rather than a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL NON-HODGKIN'S LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking University Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.